MECHELEN, BELGIUM and BARCELONA, SPAIN--(Marketwire - January 25, 2012) -
* Three-year integrated drug discovery alliance is for identifying drug
development candidates for treating respiratory disease
* The value of this collaboration could reach EUR7.5 million
(ALM.MC) announced today that has formed a research alliance with
affiliate from Galapagos NV (Euronext: GLPG).
The three-year alliance is aimed at delivering drug development
directed to a key respiratory target of interest to Almirall. Under the
of the collaboration, BioFocus will apply its integrated drug
capabilities whilst Almirall will bring in respiratory specific knowhow
joint experimental effort. The value of this collaboration to BioFocus
reach EUR7.5 million.
"We selected BioFocus for this alliance because of the excellent
scientific fit between both companies," said Dr. Bertil Lindmark, CSO,
Director R&D of Almirall.
"We are delighted to form a drug discovery alliance with one of Europe's
research-based pharmaceutical companies," added Dr. Chris Newton, SVP
Services and Managing Director, BioFocus.
Respiratory is a key research focus for Almirall together with
and dermatology areas where the company is especially engaged to
Almirall is an international pharmaceutical company based on innovation and
committed to health. Headquartered in Barcelona, Spain, it researches,
manufactures and commercialises its own R&D and licensed drugs with the aim
improving people's health and wellbeing.
Almirall focuses its research resources on therapeutic areas related
treatment of asthma, COPD (Chronic Obstructive Pulmonary
gastrointestinal disorders, psoriasis and other dermatological conditions.
Almirall's products are currently present in over 70 countries while
direct presence in Europe and Latin America through 12 affiliates.
For further information please visit the website at: www.almirall.com
BioFocus provides integrated drug discovery that delivers pre-clinical drug
candidates in all therapeutic areas with strong capability in
diseases, inflammatory diseases and with a growing track record of
candidates against rare and neglected diseases. BioFocus has advanced and
comprehensive drug discovery capabilities that are applied to client
deliver targets, hits, leads and candidate pre-clinical drugs. The company
employs over 220 exceptionally qualified and industry experienced
its three research centers in the UK, Switzerland and the Netherlands.
Since its foundation in 1997, BioFocus has striven to produce high quality
for its clients and this quality is assured by ISO9001 qualification
by regular, independent inspection of all BioFocus research centers. For
information visit: www.biofocus.com
Galapagos (Euronext: GLPG) (PINKSHEETS: GLPYY) is a mid-size biotechnology
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing GLPG0634,
well as one of the largest pipelines in biotech, with seven programs in
development and over 50 discovery programs. The Galapagos Group has about
employees and operates facilities in six countries, with global
Mechelen, Belgium. More info at: www.glpg.com
This release may contain forward-looking statements, including,
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions,
achievements expressed or implied by such forward-looking statements.
these uncertainties, the reader is advised not to place any undue
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly
obligation to update any such forward-looking statements in this
reflect any change in its expectations with regard thereto or any
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.